Delayed Function of Renal TransplantPhase 2NCT02658162
A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients
A Phase 2 study testing SANGUINATE and Normal Saline in people with Delayed Function of Renal Transplant, run by Prolong Pharmaceuticals.
Trial summary
Safety and efficacy study of SANGUINATE on reduction of delayed graft function (DGF) in patients who will be recipients of a donation after brain death (DBD) donor kidney. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Delayed Function of Renal Transplant
- What is being tested?
- SANGUINATE and Normal Saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 0 participants
- Where
- No sites listed yet
- Study dates
- Feb 2016to Dec 2018
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Able to understand and provide written informed consent.
- Male or female subject at least 18 years of age.
- Dialysis-dependent renal failure initiated at least 3 months prior to transplantation.
- Subject is to be the recipient of a first kidney transplant from a deceased donor (brain death criteria).
- Is able to receive intravenous infusions of study drug.
- Anticipated donor organ cold ischemia time < 30 hours.
Show all 9Show fewer
- A calculated prediction of DGF risk of least 25%.
- Females of childbearing potential must agree to use 2 forms of effective birth control regimen (at least one-barrier method) during the initial 30-day study period.
- Male subjects must agree to use condoms or other suitable means of pregnancy prevention.
Who cannot join
- Has received a blood transfusion of packed red blood cells (PRBC), other than with leukocyte-poor blood, within the 90-day period prior to screening.
- Recipient of a live donor kidney or a kidney from a donation after cardiac death (DCD) donor.
- Recipient of donor kidney preserved with normothermic machine perfusion.
- Is scheduled to undergo multi-organ transplantation.
- Has planned transplant of kidney(s) from a donor < 6 years of age.
- Has planned transplant of kidneys that are implanted en bloc (dual kidney transplant).
Show all 22Show fewer
- Has planned transplant of dual kidneys (from the same donor) transplanted not en bloc.
- Body Mass Index (BMI) > 38 kg/m2
- Machine perfused preservation donor kidney.
- Is scheduled for transplantation of a kidney from a donor who is known to have received an investigational therapy (under another Investigational New Drug) for ischemic/reperfusion injury immediately prior to organ recovery.
- Is scheduled to receive an blood type-incompatible donor kidney.
- Has undergone desensitization to remove antibodies prior to transplantation.
- Total bilirubin > 1.5 mg per dL, transaminase more than twice the upper limit of normal or evidence of hepatic insufficiency
- Has participated in an investigational study within the last 30 days or received an investigational product within 5 half-lives of the study drug administration, whichever is longest. Potential subjects participating in a strictly observational study or a study involving approved treatments should be discussed with the Medical Monitor.
- Has a history of human immunodeficiency virus (HIV)
- History or presence of active substance abuse (illicit drugs or alcohol) in the previous 6 months, as believed by the Investigator
- Presence of ECG-based evidence of acute myocardial infarction, unstable angina, decompensated heart failure, third degree heart block or cardiac arrhythmia associated with hemodynamic instability
- History or presence of any disease or psychiatric condition that in the Investigator's assessment that would increase the risk to subjects associated with study participation, drug administration or interpretation of results
- History of biopsy-confirmed malignancy within 5 years of randomization, with the exception of adequately treated basal cell or squamous cell carcinoma in situ skin lesions, carcinoma of the cervix in situ, or early detected prostate cancer.
- Female subject who is pregnant or breast feeding.
- Has a positive T- or B-cell cross-match by NIH anti-globulin lymphocytotoxicity method, if performed.
- Has a positive T- or B-cell cross-match AND donor specific anti-human leukocyte antigen (anti-HLA) antibody (DSA) detected by flow cytometry/Luminex based antigen-specific anti-HLA antibody testing, if performed.
About this study
Official title: A Randomized, Placebo-controlled, Prospective, Single-blind, Single Center Phase 2 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant
Safety and efficacy study of SANGUINATE on reduction of delayed graft function (DGF) in patients who will be recipients of a donation after brain death (DBD) donor kidney.
Read the detailed description
Sixty (60) adult subjects who will be recipients of a donation after brain death (DBD) donor kidney and who meet all eligibility criteria will be randomized 1:1 within 48 hours prior to transplant surgery to receive: two infusions of SANGUINATE at a dose of 320 mg/kg or placebo on the day of surgery and approximately 24 hours after surgery. Patients will be hospitalized for up to 5 days and the study duration will be 30 days.
- Conditions
- Delayed Function of Renal Transplant
- Being tested
- SANGUINATE, Normal Saline
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SANGUINATEDrug
Also called pegylated carboxyhemoglobin bovine
Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
Normal SalineDrug
Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
| Study group | Role | What they receive |
|---|---|---|
| SANGUINATE | Experimental | Two (2) infusions of SANGUINATE Receives: Drug: SANGUINATE |
| Normal Saline | Placebo comparator | Two (2) infusions of Normal Saline Receives: Drug: Normal Saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Reduction of delayed graft function (DGF)
Reduction of delayed draft function will be measured by the number of dialysis sessions.
Measured: 30 Days
Participants With at Least One Occurrence of Safety Composite Endpoint by Treatment Group.
Composite endpoint defined by changes in vital signs, electrocardiographic, biochemical, hematological, and urinalysis, graft loss, death and other reported adverse events and Graft Survival - 30 Days
Measured: 30 Days
Secondary outcomes (7)
Proportion of subjects requiring dialysis for any reason in the first 7 days post-transplant
Measured: 7 Days
Proportion of subjects requiring dialysis only in the first 5 days post-transplant
Measured: 5 Days
Number of days of dialysis therapy.
Measured: 30 Days
Proportion of subjects with a fall in serum creatinine.
Measured: 7 Days
Proportion of subjects with a serum creatinine greater than 3 mg/dL, but who did not require dialysis by Day 5 post-transplant
Measured: 5 Days
Change in estimated creatinine clearance before and after kidney transplantation.
Measured: 30 Days
Change in estimated glomerular filtration rate before and after kidney transplantation.
Measured: 30 Days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2016 (estimated)
- Study startFeb 2016 (estimated)
- Primary completionOct 2018 (estimated)
- Study completionDec 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Delayed Function of Renal TransplantStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 0 participants (actual)
Sponsor and investigators
- Lead sponsor
- Prolong Pharmaceuticals
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Hemant Misra, PhD, Study director, Prolong Pharmaceuticals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02658162
- Sponsor's protocol ID
- SGTP-003
- Status last verified
- May 2018
- First submitted
- 12 Jan 2016
- Last updated
- 25 May 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 25 May 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Placebo-controlled, Prospective, Single-blind, Single Center Phase 2 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant
- ClinicalTrials.gov ID
- NCT02658162
- Acronym / sponsor ID
- SGTP-003
- Conditions
- Delayed Function of Renal Transplant
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Withdrawn
- Enrolment
- 0 participants (actual)
- Lead sponsor
- Prolong PharmaceuticalsIndustry (pharma, biotech, devices)
- Study start
- Feb 2016 (estimated)
- Primary completion
- Oct 2018 (estimated)
- Study completion
- Dec 2018 (estimated)
- First posted
- 18 Jan 2016 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Safety and efficacy study of SANGUINATE on reduction of delayed graft function (DGF) in patients who will be recipients of a donation after brain death (DBD) donor kidney.
Detailed description
Sixty (60) adult subjects who will be recipients of a donation after brain death (DBD) donor kidney and who meet all eligibility criteria will be randomized 1:1 within 48 hours prior to transplant surgery to receive: two infusions of SANGUINATE at a dose of 320 mg/kg or placebo on the day of surgery and approximately 24 hours after surgery. Patients will be hospitalized for up to 5 days and the study duration will be 30 days.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| SANGUINATE | Experimental | Drug: SANGUINATETwo (2) infusions of SANGUINATE |
| Normal Saline | Placebo comparator | Drug: Normal SalineTwo (2) infusions of Normal Saline |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (9 listed)
- Able to understand and provide written informed consent.
- Male or female subject at least 18 years of age.
- Dialysis-dependent renal failure initiated at least 3 months prior to transplantation.
- Subject is to be the recipient of a first kidney transplant from a deceased donor (brain death criteria).
- Is able to receive intravenous infusions of study drug.
Key exclusion criteria (22 listed)
- Has received a blood transfusion of packed red blood cells (PRBC), other than with leukocyte-poor blood, within the 90-day period prior to screening.
- Recipient of a live donor kidney or a kidney from a donation after cardiac death (DCD) donor.
- Recipient of donor kidney preserved with normothermic machine perfusion.
- Is scheduled to undergo multi-organ transplantation.
- Has planned transplant of kidney(s) from a donor < 6 years of age.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SANGUINATEAlso: pegylated carboxyhemoglobin bovineTwo (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1 | Drug | SANGUINATE |
| Normal SalineTwo (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1. | Drug | Normal Saline |
Primary outcome
Reduction of delayed graft function (DGF)
Time frame: 30 Days
Reduction of delayed draft function will be measured by the number of dialysis sessions.
Participants With at Least One Occurrence of Safety Composite Endpoint by Treatment Group.
Time frame: 30 Days
Composite endpoint defined by changes in vital signs, electrocardiographic, biochemical, hematological, and urinalysis, graft loss, death and other reported adverse events and Graft Survival - 30 Days
7 secondary outcomes
Proportion of subjects requiring dialysis for any reason in the first 7 days post-transplant
Time frame: 7 Days
Proportion of subjects requiring dialysis only in the first 5 days post-transplant
Time frame: 5 Days
Number of days of dialysis therapy.
Time frame: 30 Days
Proportion of subjects with a fall in serum creatinine.
Time frame: 7 Days
Proportion of subjects with a serum creatinine greater than 3 mg/dL, but who did not require dialysis by Day 5 post-transplant
Time frame: 5 Days
Change in estimated creatinine clearance before and after kidney transplantation.
Time frame: 30 Days
Change in estimated glomerular filtration rate before and after kidney transplantation.
Time frame: 30 Days
Results and safety
The study was withdrawn before enrolling participants, so there are no results.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 May 2018.
Related trials for Delayed Function of Renal Transplant
Active, not recruitingPhase 2
ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function
Delayed Graft Function
Not yet recruiting
Drone Transport of Deceased-Donor Kidney Grafts Between Two French Hospitals Before Transplantation: a Pilot Safety Study
Kidney Failure, Chronic, Kidney Transplantation
Recruiting
The Impact of Intraoperative Diuretic Use on Delayed Graft Function Following Deceased Donor Renal Transplantation
Delayed Graft Function, Kidney Transplantation
Not yet recruiting
TxAccess and Dd-cfDNA for Improved Care of Patients With Delayed Graft Function
Delayed Graft Function
Recruiting
Ex Vivo Normothermic Perfusion in Kidney Transplantation.
Kidney Transplantation
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Hemant Misra, PhD study director
Prolong Pharmaceuticals
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing SANGUINATE and Normal Saline in people with Delayed Function of Renal Transplant, run by Prolong Pharmaceuticals.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 9 inclusion and 22 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: withdrawn, as of the sponsor's last update on 25 May 2018. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was withdrawn before enrolling participants, so there are no results.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Reduction of delayed graft function (DGF) (time frame: 30 Days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 May 2018.